{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.1","upperLimit":"17.1","value":"6.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Overall survival time is defined as the time from randomization to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 200 mg pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From study entry to death from any cause, assessed up to 2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}